Bioline Rx Profit Margin

Bioline Rx (BLRX) currently reports a profit margin of -256.03% as of June 2026. That compares with -15.21% in the prior-year period — down 1583.3% year over year. That is below the Healthcare sector average of 13.71%. Use the charts on this page to explore Bioline Rx's profit margin history and peer comparisons.

Bioline Rx's profit margin decreased from -15.21% to -256.03% — a 1583.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bioline Rx's profit margin of -256.03% is lower than the Healthcare sector average of 13.71%. That is roughly 1967.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Bioline Rx's current -256.03% should be judged against Healthcare norms (sector average: 13.71%) and against BLRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -256.03%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.71%. From there, open related valuation or income-statement pages for Bioline Rx, and consider following BLRX for alerts when major investors trade the stock.